ABIOMED (ABMD) Earns “Hold” Rating from BTIG Research

BTIG Research reaffirmed their hold rating on shares of ABIOMED (NASDAQ:ABMD) in a research report report published on Sunday.

Other analysts have also recently issued research reports about the company. Zacks Investment Research raised ABIOMED from a hold rating to a buy rating and set a $220.00 target price for the company in a research report on Tuesday, November 7th. SunTrust Banks reissued a buy rating and set a $195.00 price objective on shares of ABIOMED in a research report on Wednesday, November 1st. Jefferies Group boosted their price target on ABIOMED to $250.00 and gave the stock a buy rating in a research report on Friday, January 12th. BidaskClub raised ABIOMED from a hold rating to a buy rating in a research report on Thursday, January 11th. Finally, Piper Jaffray Companies reiterated a buy rating on shares of ABIOMED in a research note on Thursday, January 4th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. ABIOMED presently has an average rating of Buy and an average price target of $263.86.

Shares of ABIOMED (NASDAQ:ABMD) opened at $232.11 on Friday. The company has a market capitalization of $10,260.00, a price-to-earnings ratio of 117.23, a PEG ratio of 3.22 and a beta of 0.36. The company has a quick ratio of 4.98, a current ratio of 5.60 and a debt-to-equity ratio of 0.02. ABIOMED has a 12-month low of $107.33 and a 12-month high of $255.42.

ABIOMED (NASDAQ:ABMD) last issued its earnings results on Thursday, February 1st. The medical equipment provider reported $0.70 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.20. The business had revenue of $154.00 million during the quarter, compared to analysts’ expectations of $154.00 million. ABIOMED had a return on equity of 15.54% and a net margin of 16.58%. ABIOMED’s revenue was up 34.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.34 earnings per share. research analysts expect that ABIOMED will post 2.45 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the stock. Crow Point Partners LLC bought a new position in ABIOMED during the fourth quarter valued at about $120,000. Cerebellum GP LLC bought a new position in ABIOMED during the fourth quarter valued at about $127,000. Advisor Partners LLC bought a new position in ABIOMED during the fourth quarter valued at about $209,000. SeaCrest Wealth Management LLC bought a new position in ABIOMED during the fourth quarter valued at about $183,000. Finally, Flagship Harbor Advisors LLC bought a new position in ABIOMED during the fourth quarter valued at about $242,000. Hedge funds and other institutional investors own 90.65% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://sportsperspectives.com/2018/02/07/abiomed-abmd-earns-hold-rating-from-btig-research.html.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Analyst Recommendations for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply